Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 38

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 38
---
 2017, where he obtained the position of Executive Director, Head of Cancer Bioscience. In this role, Dr. Zinda served on the global science leadership team, oncology research board and the Acerta research and early development teams accountable for strategy, key collaborations/partnerships and delivery of an innovative portfolio of patient-centric drug discovery programs. Dr. Zinda holds a B.Sc. in biology from Minnesota State University Moorhead and a Ph.D. in molecular biology from Vanderbilt University. He received his post-doctoral training at Princeton University and Eli Lilly & Company. 26

EXECUTIVE COMPENSATION We are a “smaller reporting company” under Item 10 of Regulation S-Kpromulgated under the Exchange Act. Pursuant to applicable SEC rules, we have elected to continue to rely on the scaled disclosure requirements for smaller reporting companies through the filing of our Annual Report on Form 10-K,including the information in this proxy statement required by Part III of Form 10-Kand incorporated by reference therein. Accordingly, the following compensation disclosure is intended to comply with the requirements applicable to smaller reporting companies. Although the rules allow us to provide less detail about its executive compensation program, the compensation committee is committed to providing the information necessary to help shareholders understand its executive compensation-related decisions. Accordingly, this section includes supplemental narratives that describe the 2024 executive compensation program for the following individuals, collectively referred to herein in this proxy statement as our “named executive officers” for the year ended December 31, 2024:

| • |     | Lloyd M. Segal, our former President and Chief Executive Officer; |

| • |     | Maria Koehler, M.D., Ph.D., our former Executive Vice President, Chief Medical Officer; and |

| • |     | Michael Zinda, Ph.D., our Executive Vice President, and Chief Scientific Officer. |

2025 Strategic Re-Prioritization As previously disclosed, in the first quarter of 2025 we announced a re-alignmentof resources and a re-prioritizationof our clinical portfolio, as well as approved a plan to reduce our overall workforce by approximately 75%. In connection with these activities, Dr. Koehler departed from her position as our Executive Vice President and Chief Medical Officer effective March 31, 2025. Mr. Segal resigned as our President and Chief Executive Officer effective April 11, 2025. As described below under “Certain Post-Fiscal Year-End 2024 Actions”, on March 31,